Ethos Treatment Planning (2.0)

by Varian Medical Systems  · Based in United States → — Adaptive Intelligence for Personalized Cancer Radiotherapy
Oncology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Ethos Treatment Planning (2.0) by Varian Medical Systems, a Siemens Healthineers company, is an advanced, AI-driven adaptive radiotherapy system designed to revolutionize cancer treatment. It optimizes treatment planning and delivery by allowing clinicians to make daily adjustments to treatment plans based on real-time changes in a patient’s anatomy, such as tumor size or organ movement.

The system leverages artificial intelligence for enhanced planning and segmentation, significantly reducing the need for time-consuming manual contouring by automatically segmenting over 70 anatomical structures in various body regions when used with HyperSight imaging. Ethos 2.0 aims to increase the capability, flexibility, and efficiency of radiotherapy, enabling the delivery of an entire adaptive treatment, from patient setup through treatment, in typical 15-minute time slots. It supports both online and offline adaptation, as well as conventional image-guided radiotherapy (IGRT), intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), and stereotactic body radiotherapy (SBRT).

Ethos integrates with Varian’s ARIA CORE oncology management solution for seamless clinical treatment data capture and progress updates, enhancing overall clinical and operational efficiencies. The system is designed to provide high confidence in visualizing patient anatomy and acting upon anatomical changes, ensuring accurate dose calculation and efficient treatment delivery.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-driven adaptive treatment planning and delivery
  • Daily treatment plan adaptation based on patient anatomy changes
  • Enhanced algorithms for optimized treatment planning and dose delivery
  • HyperSight imaging integration for direct dose calculation (optional feature on Ethos v2.0)
  • Expanded AI-segmented anatomical structures (70+ in various body regions with HyperSight)
  • Seamless data sharing and exchange with ARIA CORE oncology management solution
  • Flexibility in treatment technique: adaptive, IGRT, IMRT, VMAT, SBRT
  • Leverages diagnostic MR, PET, and CT images during planning and treatment
  • Supports online or offline adaptation
  • Fast treatment sessions (e.g., 15-minute adaptive treatments)

Use Cases

  • Adaptive radiotherapy for various cancer types
  • Precision treatment for prostate cancer
  • Targeted therapy for lung cancer
  • Adaptive planning for bladder cancer
  • Treatment of head and neck cancers with daily adjustments
  • Radiotherapy for pancreatic and liver cancers where anatomy changes frequently

What Physicians Need to Know

Key Capabilities
AI-driven adaptive radiation therapy (ART) for personalized, real-time treatment adjustments based on daily anatomical changes. Features AI-enhanced image segmentation and auto-contouring for over 70 anatomical structures (head & neck, thorax, abdomen, pelvis, bowel regions). Utilizes an Intelligent Optimization Engine (IOE) for AI-driven treatment planning and optimization, supporting adaptive, IGRT, IMRT, VMAT, and SBRT techniques. Integrates diagnostic quality MR, PET, and CT images, and offers HyperSight imaging for direct dose calculation on CBCT images. Aims for fast treatment plan generation and adaptation, often within minutes while the patient is on the couch. Includes a High-Fidelity (HF) mode for stereotactic planning to improve dose conformity and reduce normal tissue exposure.
Clinical Utility
Enables more precise tumor targeting while sparing healthy tissue, particularly beneficial for cancers where tumor or surrounding anatomy may shift (e.g., prostate, lung, bladder, gynecologic, kidney, pancreatic cancers). Facilitates personalized treatment delivery by adapting to daily anatomical changes, leading to improved patient outcomes. Reduces the need for time-consuming manual contouring, enhancing efficiency and accuracy in treatment planning. Allows for the safe and precise delivery of higher radiation doses in complex cases.
Integration Options
Designed for seamless data sharing and exchange with Varian's ARIA CORE oncology management solution. The Ethos Treatment Management (ETM) system functions as both a treatment planning system (TPS) and an Oncology Information System (OIS). It can be implemented in multi-vendor clinics, allowing non-adaptive plans from other TPS (e.g., RayStation) to be transferred to Ethos for delivery.
Compliance Status
Received U.S. FDA 510(k) clearance for new functionalities in Ethos 2.0. Classified as a Class II medical device (21 CFR 892.5050). The software is considered by the FDA to have a 'major' level of concern, indicating that a failure could potentially result in serious injury or death. Undergoes formal design verification and validation testing to ensure safety and effectiveness.
User Experience
Offers a streamlined and guided workflow for daily treatment adaptation, aiming to reduce complexity. Can decrease plan complexity with features like High-Fidelity mode. While the system aims for a 15-20 minute adaptive treatment slot, actual on-table time can range from 40-60 minutes. Some users note a significant upfront time investment is required to develop workable radiation therapy intents.
Implementation Complexity
Aims to reduce the overall complexity of implementing adaptive radiotherapy. Can be integrated into existing multi-vendor clinic environments, though this may require specific solutions to manage potential workload increases from redundant systems. Requires a substantial initial effort to develop and customize radiation therapy intent templates for optimal use.
Evidence Base
Supported by clinical studies and publications assessing the efficacy of its Intelligent Optimization Engine (IOE) and the dosimetric benefits of its High-Fidelity mode. Varian's internal data indicates that providers chose the adapted treatment plan 88% of the time, finding it more beneficial for patients. Planning directive templates are developed based on high-quality, multi-institutional clinical trials and expert consensus guidelines. The system has passed clinical trial credentialing for dose computation.
Physician Tip

Leverage Ethos 2.0 for its robust AI-driven adaptive capabilities, especially for tumors in areas prone to anatomical changes (e.g., prostate, lung, GI tract) to maximize dose precision and healthy tissue sparing. Invest time upfront in developing comprehensive 'RT intents' and planning templates to streamline daily adaptive workflows. While the system offers significant automation, always maintain clinical oversight and review AI-generated contours and plans. Consider its versatility for both online and offline adaptation, as well as conventional IGRT, to optimize its use across various patient needs.

Ethos 2.0 is designed for tight integration with Varian's ARIA oncology management system, facilitating seamless data flow. While it can operate in multi-vendor environments, be prepared for potential workflow adjustments and data transfer considerations if integrating with non-Varian treatment planning or oncology information systems. The system's enhanced connectivity aims to reduce previous complexities in data sharing.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentOn-premise
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Varian received 510(k) clearance (K232923) from the U.S. Food and Drug Administration (FDA) for new functionality to its Ethos therapy system, including Ethos Treatment Planning (2.0) and Ethos Treatment Management (3.0), on April 30, 2024. This clearance covers enhanced algorithms, integration of HyperSight imaging for direct dose calculation, and expanded AI-segmented anatomical structures.
Integrations
EHR Not specified
Specialties Oncology

What the Web Says

Ethos Treatment Planning (2.0) by Varian is generally well-received for its adaptive therapy capabilities and integration with existing Varian systems. It aims to streamline the re-planning process for radiation therapy, allowing for on-table adaptive adjustments based on daily patient anatomy.

Overall: Positive

Strengths

  • Enables on-table adaptive radiation therapy, improving treatment precision.
  • Seamless integration with Varian TrueBeam and other Varian linacs.
  • User-friendly interface for efficient re-planning.
  • Reduces the time required for adaptive planning compared to traditional methods.
  • Potential for improved patient outcomes due to personalized daily treatments.
  • Automated contouring and dose calculation features.

Limitations

  • Can have a steep learning curve for new users.
  • Requires significant investment in Varian hardware and software ecosystem.
  • Some users report occasional software glitches or crashes.
  • Dependency on Varian's proprietary systems limits interoperability with other vendors.
  • Initial setup and calibration can be complex and time-consuming.
  • Limited feedback on long-term maintenance and support costs.

Based on reviews from: Varian Medical Systems product information, Physician forums and discussions, Healthcare IT reviews, Medical technology publications, Reddit discussions (r/medicalphysics, r/radonc), G2 reviews (general healthcare software reviews)

Last updated: 2026-07-21

Ratings & Reviews

Rate Ethos Treatment Planning (2.0)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

FDA.report
Ethos Treatment Management (3.0); Ethos Treatment Planning (2.0) - FDA 510(k) Premarket Notification
Varian Medical Systems received FDA clearance for Ethos Treatment Management 3.0 and Ethos Treatment Planning 2.0 on April 30, 2024. These software applications are designed to assist clinicians in managing, generating, and modifying radiation therapy treatment plans, incorporating AI-based segmentation algorithms.
2024-04
X-ray Interpreter
Varian Medical Systems - Radiology AI Companies
Ethos Treatment Management 3.0 and Ethos Treatment Planning 2.0 from Varian Medical Systems are software applications that incorporate AI-based segmentation algorithms to improve and streamline radiation therapy planning and monitoring. These tools aim to enhance accuracy and efficiency in radiation treatment for cancer.
2024-04
Cyber Security Agency of Singapore
Varian Ethos Treatment Planning | Cyber Security Agency of Singapore
Ethos Treatment Planning 2.0, manufactured by Varian Medical Systems Pacific, Inc., has a CLS(MD) Registration ID of CSA/MDX00010 with an issuance date of November 17, 2025, and an expiration date of November 16, 2028. It is classified as a Class C medical device by HSA.
2025-11
Radiology AI Tools Directory
Radiotherapy planning imaging radiology AI tools | FDA-cleared directory
Ethos Treatment Management (3.0) and Ethos Treatment Planning (2.0) by Varian Medical Systems Inc. are listed as FDA-cleared image analysis/processing tools for radiotherapy planning imaging. The decision date for their clearance was April 30, 2024.
2024-04
FDA
K232923 - Ethos Treatment Management (3.0); Ethos Treatment Planning (2.0)
This FDA 510(k) Premarket Notification details the clearance of Ethos Treatment Management (3.0) and Ethos Treatment Planning (2.0) by Varian Medical Systems, Inc. The submission was made by Lynn Allman and the regulation number is 892.5050.
2024-04

Videos

Product demos, reviews, and walkthroughs for Ethos Treatment Planning (2.0).

Loading videos...

View all on YouTube

Frequently Asked Questions

Ethos Treatment Planning (2.0) utilizes AI for adaptive radiotherapy, enabling real-time adjustments to treatment plans based on daily changes in a patient's anatomy. The AI solution identifies and segments organs, healthy tissue, and cancerous tissue from real-time images, then computes a new dose plan tailored to the patient, significantly speeding up the planning process from days to minutes.
Varian received FDA 510(k) clearance for its Ethos therapy system, including new functionalities in Ethos 2.0, indicating its adherence to medical device regulations. While specific data privacy protocols would be governed by institutional policies, the system is designed to integrate with oncology management solutions like ARIA CORE for seamless and secure data sharing.
Alternatives to Ethos 2.0 include traditional radiation therapy planning methods and other adaptive radiotherapy systems. Ethos 2.0 differentiates itself through its 'Adaptive Intelligence' solution, which uses AI and machine learning to automate contouring and plan optimization, allowing for on-couch adaptive treatment delivery within a typical 15-minute timeslot, a significant reduction compared to conventional re-planning processes.
While specific pricing models for Ethos 2.0 are not publicly disclosed, it represents a significant capital investment for healthcare institutions. The cost-benefit considerations include enhanced precision and efficacy of adaptive radiation treatments, improved patient experience through reduced treatment times and minimized side effects, and optimized clinical and operational efficiencies by streamlining workflows and potentially treating more patients.
Limitations include the necessity for continuous physician review and supervision of AI-driven outputs, as the optimization process is largely automated. Studies have also noted that while Ethos plans are generally of good quality, certain plan types (e.g., VMAT for head and neck) might have inferior target coverage compared to IMRT plans, and challenges exist with large density changes in areas like the lung, requiring careful quality assurance.
Ethos 2.0 is designed as an 'Adaptive Intelligence' solution, meaning AI augments, rather than replaces, human expertise. Physicians define clinical intent using predefined templates and maintain supervision over the AI-generated plans, reviewing and approving them before treatment delivery. This ensures that while AI streamlines complex tasks like segmentation and dose calculation, the ultimate clinical decision-making remains with the physician.

Related Tools

Visiopharm AI-driven Precision Pathology
Visiopharm
Oncology AI
Visiopharm provides AI-driven precision pathology software for research and diagnostics, offering image analysis applications for metastasis detection and biomarker evaluation.
DeepHeme
Memorial Sloan Kettering Cancer Center (developed in collaboration with UCSF and UC Berkeley)
Lab & Diagnostics
DeepHeme is an AI tool developed by Memorial Sloan Kettering Cancer Center, UCSF, and UC Berkeley that automates the counting and classification of blood and bone marrow cells to assist in the diagnosis of blood cancers, reducing manual review time and achieving expert-level accuracy.
ScreenPoint Medical
ScreenPoint Medical
Clinical Decision Support & Reference
ScreenPoint Medical offers Transpara, an AI-powered solution for breast cancer detection and diagnosis in mammography and digital breast tomosynthesis, designed to assist radiologists.
INIFY Prostate
ContextVision
Clinical Decision Support & Reference
INIFY Prostate is an AI-based decision support tool that accurately outlines suspicious prostate cancer areas in digitalized prostate biopsy samples.
Cartesion Prime (PCD-1000A/3) V10.21
Canon Medical Systems USA, Inc.
Clinical Decision Support & Reference
The Cartesion Prime (PCD-1000A/3) V10.21 is a premium, air-cooled digital PET/CT scanner from Canon Medical Systems, featuring AI-assisted deep learning reconstruction (AiCE) for superior image quality, faster scans, and reduced dose.
DERM (by Skin Analytics)
Skin Analytics
Clinical Decision Support & Reference
DERM is an AI as a Medical Device (AIaMD) with Class III CE mark that assesses dermoscopic images of skin lesions to provide a suspected diagnosis and referral recommendation, aiming to triage patients and reduce waiting times for skin cancer assessment.

See all Oncology AI tools →

More from Varian Medical Systems

AI Segmentation
Varian Medical Systems
Oncology AI
Varian's AI Segmentation is a web-based, AI-powered tool that automates and accelerates the contouring of organs at risk and other anatomical structures from CT images for radiation therapy planning, seamlessly integrating with Varian's Eclipse system.
Ethos Treatment Management (3.0)
Varian Medical Systems
Clinical Decision Support & Reference
Ethos therapy is an artificial intelligence (AI)-driven system designed to increase the capability, flexibility and efficiency of radiotherapy, delivering an entire adaptive treatment in a typical 15-minute timeslot, from patient setup through treatment delivery.
Contact vendor for pricing.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.